Literature DB >> 21406724

DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction.

Michele Ardolino1, Alessandra Zingoni, Cristina Cerboni, Francesca Cecere, Alessandra Soriani, Maria Luisa Iannitto, Angela Santoni.   

Abstract

An important role for natural killer (NK) cells in the regulation of T-cell responses is emerging, although the receptor pairs regulating the NK-T-cell interaction have still not been identified. We found that superantigen-stimulated T cells express Nectin-2 (CD112) and poliovirus receptor (PVR; CD155), the ligands of the activating NK receptor DNAX accessory molecule-1 (DNAM-1; CD226). Interestingly, only PVR was present at the T cell surface, particularly on cells in the S and G(2)/M phases of the cell cycle. The up-regulation of PVR expression involves DNA-damage response (DDR)-dependent pathways, because we found that pharmacologic inhibition of ATM and ATR kinases reduced PVR expression and that PVR was almost exclusively induced on cells expressing the DDR marker γH2AX. Oxidative stress contributed to DDR activation, and our results showed impaired PVR levels in the presence of the reactive oxygen species (ROS) scavenger N-acetyl-cysteine (NAC), being monocytes the main ROS source needed for optimal PVR expression on activated T cells. Interestingly, in accordance with ligand expression, NK cells lysed allogeneic proliferating more efficiently than nonproliferating T lymphocytes, with a mechanism requiring the cooperation between DNAM-1 and NKG2D. These results could contribute to unraveling the role of NK cells in the down-regulation of T-cell responses in physiologic and pathologic processes such as autoimmunity or GVHD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21406724     DOI: 10.1182/blood-2010-08-300954

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  58 in total

1.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 2.  Boosting vaccine efficacy the natural (killer) way.

Authors:  Carolyn E Rydyznski; Stephen N Waggoner
Journal:  Trends Immunol       Date:  2015-08-10       Impact factor: 16.687

3.  Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.

Authors:  Giovanni F Torelli; Nadia Peragine; Sara Raponi; Daria Pagliara; Maria S De Propris; Antonella Vitale; Alice Bertaina; Walter Barberi; Lorenzo Moretta; Giuseppe Basso; Angela Santoni; Anna Guarini; Franco Locatelli; Robin Foà
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

4.  Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.

Authors:  Cedric Menard; Luciano Pacelli; Giulio Bassi; Joelle Dulong; Francesco Bifari; Isabelle Bezier; Jasmina Zanoncello; Mario Ricciardi; Maelle Latour; Philippe Bourin; Hubert Schrezenmeier; Luc Sensebé; Karin Tarte; Mauro Krampera
Journal:  Stem Cells Dev       Date:  2013-02-25       Impact factor: 3.272

Review 5.  Molecular mechanisms of natural killer cell activation in response to cellular stress.

Authors:  C J Chan; M J Smyth; L Martinet
Journal:  Cell Death Differ       Date:  2013-04-12       Impact factor: 15.828

6.  Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.

Authors:  Christopher A Fuhrman; Wen-I Yeh; Howard R Seay; Priya Saikumar Lakshmi; Gaurav Chopra; Lin Zhang; Daniel J Perry; Stephanie A McClymont; Mahesh Yadav; Maria-Cecilia Lopez; Henry V Baker; Ying Zhang; Yizheng Li; Maryann Whitley; David von Schack; Mark A Atkinson; Jeffrey A Bluestone; Todd M Brusko
Journal:  J Immunol       Date:  2015-05-20       Impact factor: 5.422

Review 7.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 8.  Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.

Authors:  Hauke Stamm; Jasmin Wellbrock; Walter Fiedler
Journal:  Mamm Genome       Date:  2018-08-21       Impact factor: 2.957

Review 9.  DNA damage, tumor mutational load and their impact on immune responses against cancer.

Authors:  Michalis Liontos; Ioannis Anastasiou; Aristotelis Bamias; Meletios-Athanasios Dimopoulos
Journal:  Ann Transl Med       Date:  2016-07

Review 10.  Chemical metabolic inhibitors for the treatment of blood-borne cancers.

Authors:  Martin Villalba; Nuria Lopez-Royuela; Ewelina Krzywinska; Moeez G Rathore; Robert A Hipskind; Houda Haouas; Nerea Allende-Vega
Journal:  Anticancer Agents Med Chem       Date:  2014-02       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.